Monoclonal antibody therapy for Kawasaki disease: A protocol for systematic reviews and meta-analysis

被引：3

作者：

Nomura O. ^{[1
]}

Fukuda S. ^{[2
]}

Ota E. ^{[3
]}

Ono H. ^{[4
]}

Ishiguro A. ^{[5
]}

Kobayashi T. ^{[6
]}

机构：

[1] Division of Pediatric Emergency Medicine, Tokyo Metropolitan Children's Hospital, 2-8-29, Musasidai, Fuchu-shi, Tokyo

[2] Department of Pediatrics, Kawakita General Hospital, 1-7-3, Asagaya-kita, Suginami-ku, Tokyo

[3] Department of Health Policy, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, Tokyo

[4] Division of Cardiology, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, Tokyo

[5] Department of General Pediatrics and Interdisciplinary Medicine, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, Tokyo

[6] Division of Clinical Research Planning, Department of Development Strategy, Center for Clinical Research and Development, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, Tokyo

来源：

Systematic Reviews | / 5卷 / 1期

关键词：

Coronary artery abnormality; Kawasaki disease; Meta-analysis; Monoclonal antibody agents; Systematic review;

D O I：

10.1186/s13643-016-0236-2

中图分类号：

学科分类号：

摘要：

Background: Kawasaki disease (KD) is a form of self-limiting vasculitis that causes coronary artery abnormality in children. Based on reports of elevated plasma level of cytokines such as tumor necrosis factor-a in KD patients, clinical trials of monoclonal antibodies that block cytokine cascades have been conducted. However, the studies have revealed contradictory results. The objective of this study is to examine the effectiveness of treatment with monoclonal antibodies for KD patients. Methods: Relevant randomized controlled trials (RCTs), cluster RCTs, quasi-RCTs, cross-over trials, and any observational studies (e.g., cohort studies, case-control studies, case series, and case reports) will be included to summarize available evidence both qualitatively and quantitatively. Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and ICUSHI will be searched. We will assess coronary artery and treatment outcomes of the interventions. Two authors will independently screen studies for inclusion and consulting with a third author where necessary to resolve discrepancies. The risk of bias of included studies will be assessed using the Cochrane Collaboration risk of bias tool and quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Meta-analysis of the included studies will be conducted using fixed effects or random effects models depending on the degree of between-study heterogeneity. Results will be presented using risk ratios with 95 % confidence interval (CI) for dichotomous outcomes and standardized mean differences with 95 % CI for continuous outcomes. Discussion: This systematic review and meta-analysis protocol does not require ethical approval. We will disseminate the findings of this systematic review and meta-analysis via publications in peer-reviewed journals. © 2016 Nomura et al.

引用

共 23 条

[1]

Burns J.C., Glode M.P., Kawasaki syndrome, Lancet, 364, 9433, pp. 533-544, (2004)

[2]

Kawasaki T., Kosaki F., Okawa S., Et al., A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan, Pediatrics, 54, 3, pp. 271-276, (1974)

[3]

The 23rd nationwide survey of Kawasaki disease in Japan

[4]

Eleftheriou D., Levin M., Shingadia D., Et al., Management of Kawasaki disease, Arch Dis Child, 99, pp. 74-83, (2014)

[5]

Jeffes E.W., Ininns E.K., Schmitz K.L., Et al., The presence of antibodies to lymphotoxin and tumor necrosis factor in normal serum, Arthritis Rheum, 32, pp. 1148-1152, (1989)

[6]

Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version), Pediatr Int, 56, 2, pp. 135-158, (2014)

[7]

Newburger J.W., Takahashi M., Gerber M.A., Et al., Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association, Pediatrics, 114, 6, pp. 1708-1733, (2004)

[8]

Burns J.C., Capparelli E.V., Brown J.A., Et al., Intravenous gamma-globulin treatment and retreatment in Kawasaki disease, Pediatr Infect Dis J, 17, 12, pp. 1144-1148, (1998)

[9]

Nakamura Y., Yashiro M., Uehara R., Et al., Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey, J Epidemiol, 20, 4, pp. 302-307, (2010)

[10]

Fujimaru T., Ito S., Masuda H., Et al., Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange, Cytokine, 70, pp. 156-160, (2014)

← 1 2 3 →